Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 12/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068138 | 1.00 | DDB1 (0.41) | DDB1CRBNCYP11B1CYP11B2CYP1A2 | |
| SCHEMBL29348692 | 0.94 | DDB1 (0.41) | DDB1CRBNPDCD1CD274CHRM1 | |
| SCHEMBL31068153 | 0.94 | DDB1 (0.41) | DDB1CRBNPDCD1CD274CHRM1 | |
| SCHEMBL31068157 | 0.90 | DDB1 (0.39) | DDB1CRBNPDCD1CD274BRD4 | |
| SCHEMBL31068224 | 0.89 | DDB1 (0.45) | DDB1CRBNPDCD1CD274BRD4 | |
| SCHEMBL29348686 | 0.89 | DDB1 (0.45) | DDB1CRBNPDCD1CD274BRD4 | |
| SCHEMBL31068233 | 0.87 | DDB1 (0.39) | DDB1CRBNPDCD1CD274CHRM1 | |
| SCHEMBL29348698 | 0.87 | DDB1 (0.39) | DDB1CRBNPDCD1CD274CHRM1 | |
| SCHEMBL38664517 | 0.85 | DDB1 (0.39) | DDB1CRBNPDCD1CD274 | |
| SCHEMBL38665380 | 0.85 | DDB1 (0.41) | DDB1CRBNPDCD1CD274CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |